Advertisement

Why Moderna Stock Climbed Today

Shares of Moderna (NASDAQ: MRNA) rose 3.3% on Monday after health regulators in the U.K. authorized the biopharmaceutical leader's bivalent COVID-19 vaccine booster for use in adults. Moderna's updated vaccine targets the original coronavirus strain and the currently fast-spreading omicron variants. On Monday, the Medicines and Healthcare products Regulatory Agency (MHRA) said the new bivalent booster meets its "standards of safety, quality, and effectiveness."